Thurston, Springer, Miller, Herd & Titak, Inc. Ionis Pharmaceuticals Inc Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $330 Million
- Q3 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 20 shares of IONS stock, worth $769. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20
Previous 20
-0.0%
Holding current value
$769
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding IONS
# of Institutions
386Shares Held
125MCall Options Held
2.19MPut Options Held
510K-
Vanguard Group Inc Valley Forge, PA13.8MShares$533 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD12.6MShares$486 Million0.38% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$397 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.26MShares$318 Million6.59% of portfolio
-
Wellington Management Group LLP Boston, MA6.57MShares$253 Million0.06% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $5.46B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...